Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CCDC68
REST API REST API
Homo sapiens
CCDC68 is differentially expressed in 182 experiments: 108 organism parts: lung, liver, ... (106 more);, 156 disease states: normal, glioblastoma, ... (154 more);, 59 cell types 305 cell lines 25 compound treatments and 54 other conditions.
Synonyms SE57-1
Orthologs Ccdc68 (Mus musculus)   CCDC68 (Bos taurus)   Ccdc68 (Rattus norvegicus)   NP_001120389.2 (Xenopus laevis)   CCDC68 (Canis familiaris)   (Compare orthologs)
UniProt Accession Q9H2F9
Search EB-eye ENSG00000166510
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (29 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-GEOD-18005, E-GEOD-2509
MCF-7
2
E-GEOD-20081, E-GEOD-3529
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MOLT4
2
E-MTAB-62, E-MTAB-37
WI38
2
E-MTAB-62, E-MTAB-37
HL-60
1
2
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
299 more value(s).


Cell type

studied in E-GEOD-21612, E-MEXP-66, E-GEOD-20677, E-GEOD-13987, E-TABM-34, ... (30 experiments)

Factor Value U/D Experiments
basal cell
1
E-GEOD-3998
spheroid
1
E-GEOD-21612
fibroblast
1
E-GEOD-26672
naive B cell
1
E-TABM-702
monocyte at intermediate differentiation stage
1
E-GEOD-5099
plasmablast
1
E-MEXP-2360
53 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2549, E-TABM-15, E-GEOD-16363, ... (38 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
control
2
E-GEOD-16363, E-GEOD-20295
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
glioblastoma
2
3
E-GEOD-4290, E-GEOD-6014, E-MEXP-567, E-MTAB-62, E-MTAB-37 ... (5 experiments)
squamous cell cancer
1
E-MTAB-62
150 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5542, E-GEOD-5824, E-TABM-868, E-GEOD-5099, ... (14 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-5099, E-GEOD-5542, E-TABM-868, E-MEXP-1958, E-GEOD-5824, ... (6 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
unknown
1
E-GEOD-7307
actinomycin D
1
E-GEOD-6400
oligomycin
1
E-MEXP-2285
vanadium pentoxide
1
E-GEOD-5339
19 more value(s).


Biosource provider

studied in E-MTAB-37

Factor Value U/D Experiments
DSMZ
1
E-MTAB-37
ECACC
1
E-MTAB-37


BioSourceProvider
studied in E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-5372, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-GEOD-2666, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-2509, E-GEOD-21138, ... (6 experiments)

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-MEXP-421, E-TABM-868, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-GEOD-20504, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-TABM-325, E-TABM-176, E-GEOD-1432, E-TABM-666, E-GEOD-6919, ... (14 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-17400

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Media
studied in E-GEOD-21612

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-21750

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

RNAi
studied in E-MEXP-2115, E-GEOD-1676

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-16363

Strain or line
studied in E-MEXP-1996

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-2748

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541

Processing time: 0.423 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM